Precision Biosensor프리시젼바이오
335810 · KOSDAQ · ₩335810 · 프리시젼바이오
- Market cap
- ₩31B
- Enterprise value
- ₩35B
- P/E
- —
- P/B
- 0.7×
- Dividend yield
- 0.0%
- ROE
- −15.1%
- Net margin
- −26.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−59.2% from the high
₩1,106Today: ₩1,424 – ₩1,488₩3,505
Returns
- 1W−2.9%
- 1M−4.4%
- 3M+19.3%
- 6M−36.8%
- YTD−46.1%
- 1Y−47.5%
- Volume today
- 11,106
- 1.5× the 20-day average
- Traded today
- ₩16M
- Listed shares
- 21,949,506
- EPS (12 months)
- −₩289
- Earnings yield −20.2%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49 of 100 (50 is a normal day for this stock).
- MomentumWeak-5.9% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Precision Biosensor stock overview
Precision Biosensor (프리시젼바이오, KRX: 335810) is listed on KOSDAQ, in the Medical & precision devices sector. The company is an in-vitro diagnostics (IVD) specialist that provides clinical diagnostic solutions based on detection of disease markers, with a focus on point-of-care testing. Its shares closed at ₩1,431 on Oct 29, 2026, down 0.69% on the day, giving it a market value of ₩31B.
Key facts
- Market cap
- ₩31B
- Sector
- Medical & precision devices
- Latest price change
- −0.69%
- As of
- Oct 29, 2026
- Main business
- The company is an in-vitro diagnostics (IVD) specialist that provides clinical diagnostic solutions based on detection of disease markers, with a focus on point-of-care testing.
Quick answers about Precision Biosensor
- What does Precision Biosensor do?
- The company is an in-vitro diagnostics (IVD) specialist that provides clinical diagnostic solutions based on detection of disease markers, with a focus on point-of-care testing. Its main products include immunodiagnostic analyzers and cartridges using time-resolved fluorescence and gold absorbance technologies, as well as clinical chemistry POCT products that analyze blood and other body fluids for health markers such as liver enzymes, blood sugar and cholesterol. Its products, sold through its subsidiary Nano-Ditech in the United States and in other markets, target hospitals and clinical settings, including cardiac, infectious disease and veterinary testing.
- What is the market cap of Precision Biosensor?
- The market capitalisation of Precision Biosensor was ₩31B at the close on Oct 29, 2026.
- Who are the largest shareholders of Precision Biosensor?
- According to the latest official filings, the largest reported holders are Kwangdong Pharmaceutical (50.23%, as of Feb 9, 2026); Min Jun-hong (4.46%, as of Feb 10, 2026); Hwang Gyu-yeon (1.74%, as of Feb 6, 2026).
- When is the next earnings report from Precision Biosensor?
- Korean companies rarely announce results dates in advance. Based on when Precision Biosensor filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is an in-vitro diagnostics (IVD) specialist that provides clinical diagnostic solutions based on detection of disease markers, with a focus on point-of-care testing. Its main products include immunodiagnostic analyzers and cartridges using time-resolved fluorescence and gold absorbance technologies, as well as clinical chemistry POCT products that analyze blood and other body fluids for health markers such as liver enzymes, blood sugar and cholesterol. Its products, sold through its subsidiary Nano-Ditech in the United States and in other markets, target hospitals and clinical settings, including cardiac, infectious disease and veterinary testing.
Written by AI from the company's latest annual report.
- Korean name
- 프리시젼바이오
- Themes
- Medical devices
- CEO
- 김한신
- Founded
- Sep 2009
- Listed
- Dec 2020
- Listed shares
- 21,949,506
- Fiscal year ends
- Month 12
- Website
- precision-bio.com/
Similar companies
- TSE131290 · ₩2.9T₩260,500−5.27%
- Kctech281820 · ₩1.9T₩97,500+2.09%
- Classys214150 · ₩1.7T₩26,800−0.74%
- Park Systems140860 · ₩1.6T₩228,500−0.44%
- DI003160 · ₩1.2T₩43,500+0.46%
- Curiox Biosystems445680 · ₩1T₩60,600−2.88%
- LivsMed491000 · ₩1T₩40,450−7.33%
- Seers458870 · ₩907B₩23,650−3.86%
Recent filings
See all- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityAug 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityMay 15, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before MaturityMay 8, 2026
Titles in Korean until English translations are added.
Also known as: Precision Biosensor / 프리시젼바이오 / 335810 / KRX:335810
Source: KRX statistical information